Member Info for elrico

https://twitter.com/i/timeline

Although 3 months old
Synairgen named in testimony to Homeland security.
#SNG are collating data to prove efficiency. It is important to note the company is on USA HOMELAND SECURITY RADAR.

Apologies for the late response. I have not been on the forums much of late.
As far as I know, invitations are via a recruitment site. I am sure UK associations will play a part to speed the process up.

If you have not already read my latest waffle on SBTX...https://lemminginvestors.blogspot.com/2021/01/skinbiotherapeutics-facts-are-facts-are.html

The potential for SBTX over the next few months alone is enormous, even if they keep subscriptions between 25k to 100k per day. There are illustrations in the link, not predictions.

#SNG tweets in the timeline. Including today's Numis note.
https://mobile.twitter.com/LEMMINGINVESTOR

#SNG tweets in the timeline. Including today's Numis note.
hTTps://mobile.twitter.com/LEMMINGINVESTOR

OPTI has just over 24% in SBTX. You forget the recent fundraise where OPTI was diluted even though they took part.

https://lemminginvestors.blogspot.com/2021/01/optibiotix-health-finncrap-dumped.html

Thomas,

We have done this dance before.

SOH could not anticipate the timing of H&B and Optipharm agreements landing in short order of each other. Nor could he anticipate Covid-19 which impact the SBTX share price. SOH was left with two choices; risk losing or both agreements, which are worth multiples of the placing; selling a liquid asset. He needed to sell down anyway to prepare for the proposed NASDAQ dual listing anyways. OPTI still maintains almost £12m of SBTX, all of which is now free carry. Not a piece of business, which will multi-bag from its current position in due course.

A reminder of a quote from SOH; ''If you look at our H1, we have £1.68m in the balance sheet and costs of around £100k per month. This gives us 14 -16 months without sales. We have always been prudent in any fundraiser and have raised £8.3m in total, delivering a £50m+ market cap. We are not getting a placing away now or at any time soon.''

I don't know how many times people need to be reminded of the above; it wasn't so long ago. Even if there were to be a placing, they have been for £1.5m, hardly dilutive and they have always been prudent.

I don't know any more than anyone else. Logic suggests that the company already has a healthy cash position; this is expected to grow on H2 multiplier of H1. IMHO there will not be a placing until NASDAQ unless we opt for a virtual listing with virtual shares. ??

There is an alternative; a reverse listing. We will have to wait and see.

Ted,

I rely on traffic for donations, otherwise, my long hours of research and assisting investors with queries are for nothing. Copy-pasting copyright material, especially without source address, further limits traffic, thus no chance of a contribution.

Peeps,
I have had a further comment from SA today worth adding to the article I did yesterday.
https://lemminginvestors.blogspot.com/2021/01/the-barking-mad-blogger-optibiotix.html

Dam close. SBTX is worth c£15m and will no doubt grow, in fact, could overshoot OPTI market cap if SBTX develops as I suspect it will do this year. However, the sensible will know OPTI IP will grow exponentially as new pharma-grade products are developed and or as SweetBiotix develops commercial traction. Currently, OPTI has firmer foundations, which makes it the cheaper stock until SBTX is further derisked; this will happen in the coming weeks, this I have not even the slightest doubt. The psoriasis probiotic is not a phase3 binary study.

Ah, I see. Exactly correct. I am not inside, so how would I know?

There will be new board additions, but this will not impact on 2020 FY.

Sorry, Wooly, what have I missed?

Indeed, let's not get into short term price movements, it is all about the future development of commercial tangibles adding significant value.

https://lemminginvestors.blogspot.com/2021/01/the-barking-mad-blogger-optibiotix.html

https://lemminginvestors.blogspot.com/2021/01/the-barking-mad-blogger-optibiotix.html

Wrong. As far as I am aware, the probiotic is on the route from Holland. SBTX will still be in the process of trialist selection ahead of next months start of the study.

https://lemminginvestors.blogspot.com/2021/01/my-2021-picks.html

This is the latest interview with Stuart Ashman.
https://soundcloud.com/user-957798193-127487236/stuart-ashman-ceo

Based on what? IMHO we are not likely to see £1 until confirmation of production(s) later this year, possibly by October. The obvious caveat is another commercial agreement with significant upfront payments. Until then, it is about building a sensible stake you are comfortable with. I'm as certain as an outsider can be that Stuart Ashman and his team at UoM will deliver on the next key milestones. 1 commercially viable human data from the psoriasis study 2 2x commercial launches later this year, NOT 2022 as previously suggested. 3 a 3rd commercial agreement could land at any time. All of these are significant derisk events, which obviously should lead to a significant rerating.

SA interview's https://soundcloud.com/user-957798193-127487236/sets/skinbiotherapeutics-podcasts

The trial has not started early. The probiotic will not arrive in the UK from Holland for a day or so. The process of identifying the candidates will also be underway. ETA for the trial commencement in February if my memory serves me correct.

I did suggest to some peeps there is pent up interest as interpreted from data from my blog.

Without any desire to blow smoke up my own rear, I pointed to clues of interest from 24-hour data from the blog. Here is just one snapshot.

Other data highlights OPTI better, but SBTX is by far the clearest.

https://twitter.com/LEMMINGINVESTOR/status/1347176594117431300